Foghorn doses first patient in Phase 1 combo study of FHD-286 for AML

Foghorn Therapeutics Inc.

FHD-286 in combination with decitabine or cytarabine for relapsed/refractory AML; first patient dosed.
Data from the Phase 1 combo study expected in second half of 2024.
Prior monotherapy study showed blast reductions and ANC recovery across genomic backgrounds.
Preclinical models with decitabine/cytarabine improved survival vs. single-agent controls.
Study uses 3+3 dose escalation to assess safety, tolerability, and efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.